Etzer Darout
Stock Analyst at Guggenheim
(1.92)
# 2,938
Out of 4,829 analysts
110
Total ratings
32.53%
Success rate
-7.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERV Verve Therapeutics | Maintains: Buy | $18 → $24 | $4.23 | +467.38% | 2 | Apr 15, 2025 | |
| IVA Inventiva | Maintains: Buy | $12 → $9 | $3.62 | +148.62% | 3 | Apr 4, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $82 → $20 | $6.61 | +202.57% | 4 | Mar 12, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $62 → $72 | $42.95 | +67.64% | 2 | Mar 11, 2025 | |
| BNTX BioNTech SE | Maintains: Outperform | $130 → $143 | $92.87 | +53.99% | 4 | Mar 11, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $1.55 | +93.55% | 3 | Feb 11, 2025 | |
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.13 | +76.99% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $36.17 | +10.59% | 3 | Dec 20, 2024 | |
| TRML Tourmaline Bio | Initiates: Outperform | $50 | $15.10 | +231.13% | 1 | Dec 6, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | $35 | $9.50 | +268.42% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $55 | $30.07 | +82.91% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $4.52 | +1,293.81% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.16 | +2,227.59% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $69.85 | +91.84% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $8.33 | +308.16% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $19.36 | +147.93% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $108.70 | +10.40% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $38 | $30.67 | +23.90% | 3 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 → $26 | $3.04 | +755.26% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $3.89 | +542.67% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $1.43 | +249.65% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.47 | +1,260.54% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $91 | $40.90 | +122.49% | 5 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.04 | +476.92% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $0.93 | +286.69% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $67.57 | +21.36% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.20 | +352.38% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $251.15 | -32.31% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $39.85 | +35.51% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $44.27 | -14.16% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.26 | +4,026.98% | 1 | Mar 28, 2018 |
Verve Therapeutics
Apr 15, 2025
Maintains: Buy
Price Target: $18 → $24
Current: $4.23
Upside: +467.38%
Inventiva
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.62
Upside: +148.62%
Arvinas
Mar 12, 2025
Maintains: Outperform
Price Target: $82 → $20
Current: $6.61
Upside: +202.57%
Protagonist Therapeutics
Mar 11, 2025
Reiterates: Outperform
Price Target: $62 → $72
Current: $42.95
Upside: +67.64%
BioNTech SE
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $92.87
Upside: +53.99%
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $1.55
Upside: +93.55%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.13
Upside: +76.99%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $36.17
Upside: +10.59%
Tourmaline Bio
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $15.10
Upside: +231.13%
Nurix Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $9.50
Upside: +268.42%
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $30.07
Upside: +82.91%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $4.52
Upside: +1,293.81%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.16
Upside: +2,227.59%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $69.85
Upside: +91.84%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $8.33
Upside: +308.16%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $19.36
Upside: +147.93%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $108.70
Upside: +10.40%
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $30.67
Upside: +23.90%
Sep 16, 2024
Reiterates: Outperform
Price Target: $19 → $26
Current: $3.04
Upside: +755.26%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $3.89
Upside: +542.67%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $1.43
Upside: +249.65%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.47
Upside: +1,260.54%
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $40.90
Upside: +122.49%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.04
Upside: +476.92%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $0.93
Upside: +286.69%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $67.57
Upside: +21.36%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.20
Upside: +352.38%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $251.15
Upside: -32.31%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $39.85
Upside: +35.51%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $44.27
Upside: -14.16%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.26
Upside: +4,026.98%